Literature DB >> 20429794

A 4-week oral toxicity study of an antiviral drug combination consisting of arbidol and acetaminophen in rats.

Meng Wang1, Bin Shu, Wen-Xia Bai, Jin Liu, Jun Yao, Wei-Na Pan, Yu-Ying Pan.   

Abstract

The antiviral drug combination consisting of arbidol and acetaminophen was investigated for its 4-week repeated oral administration in Sprague-Dawley rats. Groups of rats (10/sex in low-dose group, 15/sex in other three groups) were given at doses of 0, 200, 400, and 800 mg/kg/day. Clinical signs, mortality, body weight, food consumption, hematology, clinical biochemistry, macroscopic findings, organ weights, and histopathology were examined. The administration resulted in increased incidence of piloerection in most of the high-dose females and in some of the high-dose males and mid-dose females. Histopathological examinations revealed minor treatment-related change in the stomach of the high-dose animals. A decrease in body-weight gains and an increase in liver weight were observed in the mid- and high-dose groups. These treatment-related effects were reversible at the 2-week recovery period. A number of other clinical and pathological findings were not considered to be treatment related, since these changes occurred only in one sex were among the normal historical ranges, which were not supported by histopathological findings. Under the conditions of the present study, the no-observed-adverse-effect-level for 4-week oral administration to rats was considered 200 mg/kg/day, based on clinical observations, pathological findings, body-weight losses, and liver-weight changes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20429794     DOI: 10.3109/01480540903311050

Source DB:  PubMed          Journal:  Drug Chem Toxicol        ISSN: 0148-0545            Impact factor:   3.356


  5 in total

1.  Steady and temporary expressions of smooth muscle actin in hair, vibrissa, arrector pili muscle, and other hair appendages of developing rats.

Authors:  Kiyokazu Morioka; Mary Arai; Setsunosuke Ihara
Journal:  Acta Histochem Cytochem       Date:  2011-06-27       Impact factor: 1.938

Review 2.  An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment.

Authors:  Dragana Javorac; Lazar Grahovac; Luka Manić; Nikola Stojilković; Milena Anđelković; Zorica Bulat; Danijela Đukić-Ćosić; Marijana Curcic; Aleksandra Buha Djordjevic
Journal:  Food Chem Toxicol       Date:  2020-07-21       Impact factor: 6.023

Review 3.  Arbidol as a broad-spectrum antiviral: an update.

Authors:  Julie Blaising; Stephen J Polyak; Eve-Isabelle Pécheur
Journal:  Antiviral Res       Date:  2014-04-24       Impact factor: 5.970

4.  Neutralizing Effect of Synthetic Peptides toward SARS-CoV-2.

Authors:  Pedro F N Souza; Maurício F vanTilburg; Felipe P Mesquita; Jackson L Amaral; Luina B Lima; Raquel C Montenegro; Francisco E S Lopes; Rafael X Martins; Leonardo Vieira; Davi F Farias; Ana C O Monteiro-Moreira; Cleverson D T Freitas; Arnaldo S Bezerra; Maria I F Guedes; Débora S C M Castelo-Branco; Jose T A Oliveira
Journal:  ACS Omega       Date:  2022-04-28

5.  The Antiviral Drug Arbidol Inhibits Zika Virus.

Authors:  Susan L Fink; Lucia Vojtech; Jessica Wagoner; Natalie S J Slivinski; Konner J Jackson; Ruofan Wang; Sudip Khadka; Priya Luthra; Christopher F Basler; Stephen J Polyak
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.